BJDX Bluejay Diagnostics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why BJDX matters now
Bluejay Diagnostics, Inc. (BJDX) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.45 with +3.57% on the session and $657.6K in market capitalization; recent performance reads 1-month +160.82% and YTD +67.04%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-1.9M, and EPS of $-4.27. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -328.8%.
The latest indexable market news headline is "Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $—; recent insider activity includes Dey Svetlana filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.48
P/S
0.00
EV/EBITDA
0.23
DCF Value
$10.79
FCF Yield
-328.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-144.3%
ROA
-123.3%
ROIC
-163.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-1.9M | $-4.27 |
| Q4 2025 | $0.00 | $-1.4M | $-2.37 |
| FY 2025 | $0.00 | $-6.8M | $-15.25 |
| Q3 2025 | $0.00 | $-1.6M | $-4.04 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
0.82
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.